Achyut Healthcare Ltd.

Achyut Healthcare Ltd.

BBSE:ACHYUT
6.97
INR
-0.36
(-4.91%)
0.01EPS
571.76P/E
1.46BMarket Cap
Achyut Healthcare Ltd.
BSE:ACHYUT
(Bombay Stock Exchange)

Recent

price

6.97

P/E

ratio

571.76

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
0.03
0.02
0.01
0.03
0.02
0.26
0.13
0.49
0.45
Revenue per Share
- -
- -
- -
- -
- -
0.02
0.02
0.01
0.01
Basic EPS, GAAP
- -
- -
- -
-0.05
-0.03
-0.27
-0.63
-0.3
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.01
0.01
0.01
0.43
0.74
1.31
1.33
1.49
1.46
Book Value per Share
0.01
0.01
0.01
0.43
0.74
1.31
1.33
1.49
1.46
Tangible Book Value per Share
212
212
212
1,416
1,308
232
236
236
240
Basic Weighted Avg Shares
7
3
3
40
27
61
30
116
107
Sales/Revenue/Turnover
2.05
3.62
4.21
2.01
-9.88
0.49
-6.98
2.09
0.55
Operating Margin (%)
- -
- -
- -
- -
- -
- -
1
1
2
Depreciation Expense
- -
- -
- -
- -
2
5
5
3
3
Net Income, GAAP
208.96
25.93
16.64
59.9
25.3
32.23
20.86
15.99
21.4
Effective Tax Rate (%)
-2.19
4.19
3.89
1
8.58
8.18
16.89
2.72
2.36
Profit Margin (%)
2
2
2
70
95
212
86
62
26
Working Capital
- -
- -
- -
- -
- -
15
14
13
12
LT Debt
2
2
3
91
145
308
313
351
353
Total Equity
- -
4.85
4.72
-0.33
-1.69
0.09
-0.53
0.22
- -
Return on Invested Capital (%)
- -
6.98
4.68
0.86
1.97
2.15
1.67
1
- -
Return on Capital (%)
- -
6.91
4.62
0.86
1.96
2.22
1.66
0.95
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Mar'26
Jun'27
Sep'27
ST Debt
2
- -
3
LT Borrowings
- -
- -
- -
LT Finance Leases
13
- -
12
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
236
241
241
Market Capitalization
1,241
1,866
1,455

Working Capital

INR

•

in mil. unless spec.
Mar'26
Jun'27
Sep'27
Total Current Assets
79
- -
62
Cash, Cash Equivalents & STI
9
- -
14
Accounts Receivable, Net
14
- -
12
Inventories
4
- -
3
Total Current Liabilities
17
- -
36
Payables & Accruals
- -
- -
- -
ST Debt
2
- -
3
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
743.33%
12.14%
Free Cash Flow
- -
-15,358.75%
-51.71%
Net Income, GAAP
- -
166.87%
-38.66%
Sales/Revenue/Turnover
- -
341.87%
280.43%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
9
30
2026
31
25
16
44
116
2027
31
17
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
0.01
0.02
2026
- -
0.01
- -
- -
0.01
2027
0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Business
Achyut Healthcare Limited Achyut Healthcare Limited engages in the manufacturing, trading, and sale of pharmaceutical formulations, active pharmaceutical ingredients (APIs), nutraceuticals, dietary supplements, and medical devices primarily in India with exports to international markets. The company offers products in various forms including tablets, capsules, oral liquids, and injectables; specific offerings encompass generic medications, branded formulations, over-the-counter (OTC) products such as pain relievers and cold remedies, vitamins, minerals, herbal supplements, and specialty pharmaceuticals like immunosuppressants (Cenzure, Arpimune, Azathioprine IP, Everolimus, Mycophenolate Mofetil USP, Mycophenolate Sodium USP, Sirolimus, Tacrolimus USP) alongside items like infrared thermometers and ascorbic acid coated Vitamin C. It provides contract manufacturing services encompassing formulation development, scale-up production, packaging, labeling, and custom API synthesis, while ensuring quality assurance through WHO-GMP compliance and regulatory support for product registration and global distribution. Founded in 1996 and headquartered at 610 Colonade, behind Iscon Temple, opposite Iscon BRTS Bus Stand, Ahmedabad, Gujarat, India, Achyut Healthcare operates in the pharmaceuticals and healthcare sector targeting domestic and export customers including pharmaceutical companies and end-users. Recent developments include promoter Akshit M. Raychahuf increasing his stake from 1.42% to 1.44% via acquisition of 63,000 shares on November 12, 2025; regularization of independent directors Parag Dave and Rajesh Sutaria for five years and appointment of Kamlesh M Shah & Co. as secretarial auditors for 2025-2030 at the 30th AGM on October 1, 2025; and an upcoming board meeting on October 16, 2025, to approve unaudited H1 results ended September 30, 2025.